AbbVie completes acquisition of Aliada Therapeutics
AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...
PharmTech11h
AbbVie Acquires Aliada Therapeutics, Gains Neuroscience Pipeline
AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.
RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by AbbVie
RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...
Hosted on MSN1mon
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
AbbVie has agreed to buy Aliada Therapeutics, a biotechnology company backed by Johnson & Johnson, for $1.4 billion in cash in a deal that adds a potential therapy for Alzheimer’s disease to ...
Crain's Chicago Business20h
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
pharmaphorum5d
AbbVie gets bigger in Alzheimer's R&D with Aliada takeover
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...
BioSpace2d
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
FierceBiotech2d
AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing
Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...
Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership with AbbVie
Aldeyra Therapeutics (ALDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas ...
Seeking Alpha19d
AbbVie: Upgrading To 'Strong Buy' After Pullback
AbbVie continues to be a leader in the global ... its portfolio of product candidates due to the acquisition of Aliada Therapeutics at the end of October 2024 and Cerevel Therapeutics.
FierceBiotech1mon
AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS
The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...
Reuters9d
Abbvie Inc
AbbVie cuts 2024 profit forecast citing R&D expenses Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $ ...